Shares of Korro Bio jumped 10.7% to $10.28 Wednesday after the Cambridge, Mass., company reported that its experimental drug for alpha-1 antitrypsin deficiency — a genetic condition that damages both lungs and liver — achieved greater than 95% editing of the disease-causing gene's RNA and reduced toxic liver protein by up to 95% in repeat-dose mouse studies . The results are preclinical, meaning they have only been tested in animals, but they sharpen the investment case for a company valued at roughly $150 million with no approved products and no revenue from drug sales.
The Data Look Sharp, but the Drug Hasn't Reached Humans Yet. In lab-dish tests, the drug showed potent activity at very low concentrations, achieving up to 98% editing in both mouse and human liver cells . Korro plans to file for regulatory approval to begin human testing in the first half of 2027 . That means investors are pricing in a drug that is still at least a year from generating any clinical proof in patients — a critical gap where many biotech candidates fail.
The Real Edge: Tackling Both Lung and Liver Disease. Current treatments for this condition are IV infusions of replacement protein that only protect the lungs. The treatment landscape lacks curative therapies; augmentation therapy is approved only for lung disease . Korro's approach edits the defective RNA to simultaneously restore healthy protein and clear the toxic version from the liver — potentially addressing both organ systems through a single subcutaneous injection . If validated in humans, that dual benefit could carve out a distinct position in a market valued at roughly $3.3 billion in 2026 .
The Balance Sheet Buys Time — For Now. Korro held $137.9 million in cash as of June 30, with projected runway into the second half of 2028 . The company burned about $71 million over the prior year , meaning it can fund two programs through early clinical milestones without immediately diluting shareholders. But that burn rate equals roughly 42% of the company's market value, and any need to raise more cash could significantly hurt returns through dilution .
A Second Program Adds Momentum — and Risk. On October 5, Korro dosed the first patients in a Phase 1/2 trial for a separate drug targeting dangerous ammonia buildup in the blood , with an interim clinical readout expected in the second half of 2027 . Running two early-stage programs simultaneously accelerates the cash clock but also gives investors two shots at validation. Today's pop reflects genuine scientific progress — but with no human data for either asset, the stock remains a bet on the platform, not the proof.